Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

NDA FilingAzetukalnerPositive

AI Analysis

Summary

Xenon Pharmaceuticals announced the submission of an NDA to the FDA for azetukalner for the treatment of focal seizures and provided an update on its psychiatry clinical program.

Importance:7/10

Sentiment:

0.60

NDA_submissionneuroscienceseizurespsychiatry_program

Related Companies

$XENE

Read the original article

Published by Drugs.com New Drug Applications on September 17, 2026 11:09 PM

Read Original